As per the USFDA, OAI implies that the regulator may withhold approval of any pending product applications or supplements filed from such facility till the outstanding observations related to non-compliance of manufacturing norms laid down by it.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/yPDjmb1
via
Official action indicated for Biocon arm's unit in Malaysia after USFDA inspection
October 18, 2023
0
Tags
-min.png)